Text Size

The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers

This study has been completed.
Sponsor:
Information provided by:
Tel-Aviv Sourasky Medical Center
ClinicalTrials.gov Identifier:
NCT00267813
First received: December 20, 2005
Last updated: May 6, 2008
Last verified: May 2008
History of Changes

December 20, 2005
May 6, 2008
July 2004
October 2007   (final data collection date for primary outcome measure)
Brain metabolic activity (FDG) in response to craving and neutral cues. [ Time Frame: 30-40 minutes ] [ Designated as safety issue: No ]
Brain metabolic activity (FDG) in response to craving and neutral cues.
Complete list of historical versions of study NCT00267813 on ClinicalTrials.gov Archive Site
Subjective ratings of craving [ Time Frame: 10 minutes ] [ Designated as safety issue: No ]
Subjective ratings of craving
Not Provided
Not Provided
 
The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers
The Effects of Craving and Abstinence From Cigarettes on Brain Metabolism in Smokers.

Craving and withdrawal from smoking cigarettes are major factors for relapse. We investigated craving for cigarettes in smokers undergoing pharmacological treatment with Bupropion (Zyban). We compare cue-induced reactivity to smoking videos in smokers who were successfully treated with Bupropion to smokers who are still smoking. We measured the brain's metabolic activity in response to smoking and neutral cues in Positron Emission Tomography using FDG.

Craving and withdrawal from smoking cigarettes are major factors for relapse. We investigated craving for cigarettes in smokers undergoing pharmacological treatment with Bupropion (Zyban)for 2 months. We compare cue-induced reactivity to smoking videos in smokers who were successfully treated with Bupropion to smokers who are still smoking. We measured the brain's metabolic activity after exposure to videotapes showing smoking and neutral scenes in Positron Emission Tomography using FDG. There were 2 scanning sessions, one with a smoking videotape and one with a neutral video separated by a week. So far we have compared the brain's metabolic activity in 6 abstinent smokers and 6 still smokers.
Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Nicotine Dependence
Drug: Bupropion (Zyban)
1 tablet a day increasing to 2 tablets a day after a week
Not Provided
Weinstein A, Greif J, Yemini Z, Lerman H, Weizman A, Even-Sapir E. Attenuation of cue-induced smoking urges and brain reward activity in smokers treated successfully with bupropion. J Psychopharmacol. 2010 Jun;24(6):829-38. Epub 2009 Jul 31.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
24
October 2007
October 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Cigarette smokers (over 1 pack a day)
  • Age 20-65, male-females

Exclusion Criteria:

  • Dependence on other substances
  • Psychiatric diagnosis
  • Neurological disorder
  • Obesity
  • Young persons
  • Pregnant women
Both
20 Years to 65 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT00267813
TASMC-O5-EE-065-CTIL
No
Dr. Aviv M. Weinstein, Sourasky Medical Center Tel Aviv
Tel-Aviv Sourasky Medical Center
Not Provided
Principal Investigator: Einat Even-Sapir, M.D, Ph.D Tel-Aviv Sourasky Medical Center
Principal Investigator: Aviv M Weinstein, Ph.D Tel-Aviv Sourasky Medical Center
Study Director: Hedva Lerman, M.D Tel-Aviv Sourasky Medical Center
Tel-Aviv Sourasky Medical Center
May 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP